Substances
Belbuca vs Suboxone: Which One is Best For Me?
Medically Reviewed By
Written By
Last medically reviewed February 24, 2025
Substances
Medically Reviewed By
Written By
Last medically reviewed February 24, 2025
Buprenorphine medications play a vital role in recovery treatment, with Belbuca and Suboxone being well-established as two potential options. While both contain buprenorphine as their active ingredient, they have distinct differences in their formulation, administration, and typical uses in treatment. These key variations guide meaningful discussions with healthcare teams about the most appropriate choice for individual circumstances and recovery goals.
Belbuca is a prescription medication containing buprenorphine, delivered through a film that adheres to the inside of the cheek.[1] This unique delivery system allows the medication to be absorbed directly into the bloodstream through the mucous membranes. The medication is specifically designed and FDA-approved for managing chronic pain that requires daily, around-the-clock, long-term treatment when other pain treatments prove inadequate.
Unlike other buprenorphine products, Belbuca has seven different strengths, ranging from 75 to 900 micrograms, allowing doctors to precisely tailor the dose to each person’s pain management needs.[2] The film dissolves completely in the mouth and needs to be taken twice daily for consistent pain control. Healthcare experts carefully monitor and adjust dosing based on pain levels and response to treatment, ensuring optimal relief while minimizing potential side effects.
Suboxone is a prescription medication that combines two active ingredients: buprenorphine and naloxone.[3] The medication is a sublingual film that dissolves under the tongue or inside the cheek. While buprenorphine helps reduce cravings and withdrawal symptoms, naloxone acts as a safety measure to prevent misuse. Suboxone is specifically FDA-approved for treating opioid dependence as part of a complete recovery program that includes counseling and behavioral therapy.
The medication is available in four different strengths, with the buprenorphine-naloxone combinations ranging from 2 to 0.5 milligrams to 12 to 3 milligrams.[4] Healthcare teams work closely with each person to determine the right dosing schedule, typically starting with an initial dose when mild to moderate withdrawal symptoms first appear. Most people take Suboxone once daily, though some may need divided doses based on their specific treatment plan and response to the medication.
Belbuca and Suboxone serve distinctly different purposes in medical treatment, though both contain buprenorphine as their primary active ingredient. Doctors prescribe Belbuca specifically for people living with severe chronic pain who need continuous, long-term pain management.[5] The medication offers an alternative when other pain treatments have not provided adequate relief, and its varied dosing options allow for precise pain control.
Suboxone, on the other hand, plays a crucial role in medication-assisted treatment for opioid dependence.[6] Healthcare teams prescribe it as part of a comprehensive recovery plan that includes counseling and support services. The addition of naloxone in Suboxone helps prevent misuse, while the buprenorphine component works to reduce cravings and manage withdrawal symptoms. This combination makes it an effective tool for supporting long-term recovery and helping people regain stability.
Common side effects of Belbuca may include headache, nausea, constipation, vomiting, fatigue, and dizziness.[7] Some people experience redness, irritation, or discomfort in the mouth where the film is placed. More serious side effects can include respiratory depression, particularly when starting treatment or adjusting doses. Healthcare teams monitor closely for excessive drowsiness, shallow breathing, or confusion.
Suboxone’s side effects often include headache, nausea, numbness or tingling in the mouth, vomiting, constipation, and sweating.[8] The sublingual film may cause tongue pain, redness, or mouth numbness. Like Belbuca, Suboxone can cause respiratory depression, though the risk is generally lower due to its ceiling effect. Some people report sleep problems, concentration difficulties, or mood changes during treatment.
Both medications can interact with other substances, particularly alcohol, benzodiazepines, or other medications that affect the central nervous system. These interactions may increase the risk of serious side effects. It’s essential to inform healthcare teams about all current medications, supplements, and substance use to prevent dangerous interactions. They should also know about new side effects during treatment, as dosing adjustments or additional supportive care might be needed.
The primary difference between these medications lies in their intended use and formulation. Belbuca treats chronic pain, while Suboxone specifically targets opioid dependence as part of a comprehensive recovery program. Belbuca contains only buprenorphine, whereas Suboxone combines buprenorphine with naloxone to prevent misuse.
The medications also differ in their strength and dosing schedules. Belbuca offers seven strengths ranging from 75 to 900 micrograms, typically requiring twice-daily dosing for consistent pain control. Suboxone comes in four-strength combinations of buprenorphine-naloxone and usually requires once-daily dosing, though some people may need adjusted schedules.
The administration methods vary between these medications. Belbuca uses a buccal film that adheres to the inside of the cheek, while Suboxone can be placed either under the tongue or inside the cheek for absorption. These distinct delivery systems influence how the medication enters the bloodstream and affects the body. Additionally, healthcare teams approach prescribing and monitoring differently for each medication, based on whether they’re treating pain or supporting recovery.
The choice between Belbuca and Suboxone isn’t a personal decision – it depends entirely on your medical condition and treatment needs. These medications serve different purposes: Belbuca for chronic pain management and Suboxone for opioid dependence treatment. The right medication will be determined by working closely with your healthcare team.
Your healthcare team will evaluate several factors before making a recommendation, including:
The best course of action is to schedule an appointment with a qualified healthcare provider who can perform a thorough evaluation. They will discuss your situation, answer any questions about these medications, and guide you toward the most appropriate treatment option.
Both Belbuca and Suboxone contain buprenorphine, which can potentially be misused.[9] However, each has built-in safeguards – Suboxone contains naloxone that triggers withdrawal if injected, while Belbuca uses lower doses and a specific delivery system.
Healthcare providers carefully monitor usage through regular appointments, drug screenings, and proper prescribing practices. It’s essential to take these medications exactly as prescribed, never share them, and talk openly with providers about any concerns. Support is always available for those who struggle with medication use.
Most insurance plans cover both medications, but they often require prior authorization. Your healthcare provider must submit documentation explaining why the medication is necessary. Out-of-pocket costs vary widely depending on your insurance plan and whether you use brand-name or generic versions. Contact your insurance provider directly to understand your specific coverage and potential costs.
Belbuca requires twice-daily dosing, typically once in the morning and once in the evening, with doses spaced approximately 12 hours apart. The film is placed on the inside of your cheek and must be fully dissolved. Suboxone is usually taken once daily, though some people may need split doses based on their treatment plan. The film dissolves under the tongue or inside the cheek.
Yes, both medications will show up on most drug tests as they contain buprenorphine. It’s important to inform the testing facility and employer about your prescribed medication before the test. Keep a copy of your prescription or a letter from your healthcare provider explaining your authorized medication use. Most testing facilities can differentiate between prescribed use and unauthorized use.
For Belbuca: If you miss a dose, take it as soon as you remember unless it’s almost time for your next scheduled dose. Never take two doses at once to make up for a missed dose.
For Suboxone: Contact your healthcare provider immediately for guidance, as timing is crucial for maintaining stable treatment. Never double up on doses without medical supervision. Your provider will give you specific instructions based on how much time has passed since your missed dose.
[1] Belbuca (buccal film) Uses, Side Effects & Warnings. (n.d.). Drugs.com. https://www.drugs.com/belbuca.html on January 14, 2024
[2] Drugs.com. (2024). Belbuca: Package Insert / Prescribing Information. Drugs.com. https://www.drugs.com/pro/belbuca.html on January 14, 2024
[3] Velander, J. R. (2018). Suboxone: Rationale, Science, Misconceptions. The Ochsner Journal, 18(1), 23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5855417/ on January 14, 2024
[4] HIGHLIGHTS OF PRESCRIBING INFORMATION. (n.d.). https://www.suboxone.com/pdfs/prescribing-information.pdf on January 14, 2024
[5] BELBUCA® (buprenorphine buccal film) | Get Back to Life. (n.d.). Belbuca®. https://www.belbuca.com/ on January 14, 2024
[6] Velander, J. R. (2018). Suboxone: Rationale, Science, Misconceptions. The Ochsner Journal, 18(1), 23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5855417/ on January 14, 2024
[7] Why BELBUCA? | BELBUCA® (buprenorphine buccal film), CIII. (2024). Belbuca®. https://www.belbuca.com/why-belbuca on January 14, 2024
[8] Suboxone: Side effects and how to manage them. (2023, January 25). Www.medicalnewstoday.com. https://www.medicalnewstoday.com/articles/drugs-suboxone-side-effects on January 14, 2024
[9] Chilcoat, H. D., Amick, H. R., Sherwood, M. R., & Dunn, K. E. (2019). Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Journal of Substance Abuse Treatment, 104, 148–157. https://www.sciencedirect.com/science/article/pii/S0740547218304720 on January 14, 2024